Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email

Relay Therapeutics (RLAY) News Today

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)
Free RLAY Stock Alerts
$6.64
+0.13 (+2.00%)
(As of 05/17/2024 08:54 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
May 13, 2024 | globenewswire.com
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 13, 2024 | americanbankingnews.com
Relay Therapeutics (NASDAQ:RLAY) Lifted to Overweight at Barclays
May 12, 2024 | americanbankingnews.com
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up to $6.31
May 10, 2024 | msn.com
Relay Therapeutics upgraded by Barclays ahead of data readout
May 10, 2024 | msn.com
Barclays Upgrades Relay Therapeutics (RLAY)
May 10, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Raised to "Overweight" at Barclays
Barclays raised Relay Therapeutics from an "equal weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a report on Friday.
May 8, 2024 | markets.businessinsider.com
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
May 7, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 5.2%
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.2%
May 6, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among anal
May 4, 2024 | finance.yahoo.com
Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.08. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $0.12 million. Relay Therapeutics had a negative return on equity of 42.43% and a negative net margin of 1,263.49%. The firm's quarterly revenue was up 4327.9% on a year-over-year basis. During the same period last year, the company posted ($0.78) EPS.
May 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up on Earnings Beat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Earnings Beat
May 2, 2024 | finance.yahoo.com
Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
May 2, 2024 | investorplace.com
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 2, 2024 | globenewswire.com
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
April 30, 2024 | insidertrades.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 Shares
April 29, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $10,814.10 in Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $6.38, for a total value of $10,814.10. Following the completion of the transaction, the chief financial officer now owns 339,803 shares of the company's stock, valued at approximately $2,167,943.14. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
April 26, 2024 | marketbeat.com
Relay Therapeutics (RLAY) Scheduled to Post Earnings on Thursday
Relay Therapeutics (NASDAQ:RLAY) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.
April 25, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Shares Down 7.6%
Relay Therapeutics (NASDAQ:RLAY) Trading Down 7.6%
April 25, 2024 | globenewswire.com
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
April 24, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.74
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year Low at $5.74
April 18, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low at $5.95
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.95
April 17, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.9%
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9%
April 11, 2024 | globenewswire.com
Relay Therapeutics to Participate in Upcoming Investor Conferences
April 11, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and o
April 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%
Relay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%
March 27, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 6.2%
Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.2%
March 19, 2024 | markets.businessinsider.com
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
March 19, 2024 | marketbeat.com
Leerink Partnrs Comments on Relay Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:RLAY)
Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Leerink Partnrs issued their Q2 2024 earnings per share estimates for Relay Therapeutics in a research note issued on Sunday, March 17th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.64) per share for t
March 16, 2024 | finance.yahoo.com
RLAY Apr 2024 7.500 call
March 16, 2024 | finance.yahoo.com
RLAY Apr 2024 7.500 put
March 15, 2024 | investorplace.com
3 Precision Medicine Stocks That Could Benefit From the Industry's Rise
March 14, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%
March 13, 2024 | seekingalpha.com
Relay Therapeutics: Platform More Important Than Programs
March 6, 2024 | marketbeat.com
Fmr LLC Lowers Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Fmr LLC cut its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,107,733 shares of the company's stock after selling
March 4, 2024 | marketbeat.com
Trexquant Investment LP Has $1.67 Million Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Trexquant Investment LP boosted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 926.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 198,671 shares of the company's stock after buying an additional 179,317 shares durin
February 27, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Algert Global LLC
Algert Global LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 61.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,823 shares of the company's stock after purchasin
February 26, 2024 | globenewswire.com
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
February 26, 2024 | markets.businessinsider.com
Relay Therapeutics: Strong Buy on Improved Financials and Promising Future Milestones
February 25, 2024 | fool.com
Relay Therapeutics (NASDAQ: RLAY)
February 24, 2024 | finance.yahoo.com
Relay Therapeutics Full Year 2023 Earnings: Beats Expectations
February 23, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Announces Earnings Results
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 38.10%. During the same period last year, the company earned ($0.56) earnings per share.
February 23, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Sees Large Volume Increase on Better-Than-Expected Earnings
Relay Therapeutics (NASDAQ:RLAY) Sees Strong Trading Volume After Earnings Beat
February 23, 2024 | finanznachrichten.de
Relay Therapeutics, Inc.: Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
February 22, 2024 | markets.businessinsider.com
Optimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline Focus
February 22, 2024 | finance.yahoo.com
Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights
February 22, 2024 | globenewswire.com
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
February 21, 2024 | benzinga.com
Relay Therapeutics's Earnings: A Preview
February 21, 2024 | investing.com
Relay Therapeutics Inc (RLAY)
February 21, 2024 | marketbeat.com
Rafferty Asset Management LLC Lowers Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Rafferty Asset Management LLC cut its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 39.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 377,745 shares of the company's stock after selling 249,268 shares durin
Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

Global crypto currency reset (41 major banks signed up) (Ad)

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

 Here's everything you need to know.

RLAY Media Mentions By Week

RLAY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLAY
News Sentiment
▼
0.09

0.42
▲
Average
Medical
News Sentiment

RLAY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLAY Articles
This Week
▼
2

2
▲
RLAY Articles
Average Week

Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RLAY) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club